The ACCESS Consortium, an international coalition made up of the regulatory agencies for Australia, Canada, Singapore, Switzerland and the UK, has outlined how its new “promise pilot” pathway will work in practice and which types of medicines are eligible for this assessment route.
The promise pilot pathway is a priority review scheme for new medicines that meet certain criteria, such as treating a condition that is life-threatening and has no other treatment options, which sits within the
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?